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Twenty-Year Predictors of Peripheral Arterial Disease Compared With
Coronary Heart Disease in the Scottish Heart Health Extended Cohort
(SHHEC)
Hugh Tunstall-Pedoe, MD; Sanne A. E. Peters, PhD; Mark Woodward, PhD; Allan D. Struthers, MD; Jill J. F. Belch, MD
Background-—Coronary heart disease and peripheral arterial disease (PAD) affect different vascular territories. Supplementing
baseline ﬁndings with assays from stored serum, we compared their 20-year predictors.
Methods and Results-—We randomly recruited 15 737 disease-free men and women aged 30 to 75 years across Scotland
between 1984 and 1995 and followed them through 2009 for death and hospital diagnoses. Of these, 3098 developed coronary
heart disease (19.7%), and 499 PAD (3.2%). Hazard ratios for 45 variables in the Cox model were adjusted for age and sex and for
factors in the 2007 ASSIGN cardiovascular risk score. Forty-four of them were entered into parsimonious predictive models, tested
by c-statistics and net reclassiﬁcation improvements. Many hazard ratios diminished with adjustment and parsimonious modeling,
leaving signiﬁcant survivors. The hazard ratios were mostly higher in PAD. New parsimonious models increased the c-statistic and
net reclassiﬁcation improvements over ASSIGN variables alone but varied in their components and ranking. Coronary heart disease
and PAD shared 7 of the 9 factors from ASSIGN: age, sex, family history, socioeconomic status, diabetes mellitus, tobacco
smoking, and systolic blood pressure (but neither total nor high-density lipoprotein cholesterol); plus 4 new ones: NT-pro-BNP,
cotinine, high-sensitivity C-reactive protein, and cystatin-C. The highest ranked hazard ratios for continuous factors in coronary
heart disease were those for age, total cholesterol, high-sensitivity troponin, NT-pro-BNP, cotinine, apolipoprotein A, and waist
circumference (plus 10 more); in PAD they were age, high-sensitivity C-reactive protein, systolic blood pressure, expired carbon
monoxide, cotinine, socioeconomic status, and lipoprotein (a) (plus 5 more).
Conclusions-—The mixture of shared with disparate determinants for arterial disease in the heart and the legs implies nonidentical
pathogenesis: cholesterol dominant in the former, and inﬂammation (high-sensitivity C-reactive protein, diabetes mellitus, smoking)
in the latter. ( J Am Heart Assoc. 2017;6:e005967. DOI: 10.1161/JAHA.117.005967.)
Key Words: cohort study • coronary heart disease • epidemiology • peripheral arterial disease • risk prediction
O cclusive arterial atherothrombosis is common to bothcoronary heart disease (CHD) and peripheral arterial
disease (PAD), but in different vascular territories, usually in
different sized arteries. Predictors of the predominant
cardiovascular killer diseases CHD and stroke have been
extensively investigated, leaving PAD comparatively
neglected, although of increasing worldwide importance.1,2
Presenting clinically less commonly, and later in life, and
commonly missed unless looked for, PAD is harder to study.
Despite being associated with serious morbidity, and an
ominous marker for diminished survival, even in its much
more common presymptomatic form,3-5 PAD is more likely to
be classiﬁed as an associated rather than a direct cause of
death. Unlike CHD, the literature on risk factors for PAD is
dominated, with exceptions, by cross-sectional and case-
control studies featuring contemporaneous measure-
ments.1,6,7 A detailed comparison of predictors of the 2
clinical outcomes, measured in advance of disease, is made
possible within the Scottish Heart Health Extended Cohort
(SHHEC). Assay of archived serum provides many new
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biomarkers, and 20 years of follow-up provide sufﬁcient
incident cases to facilitate discrimination of these 2 cardio-
vascular end points.
Methods
Recruitment
SHHEC combines men and women of the Scottish Heart
Health Study (SHHS), aged 40 to 59 years, randomly recruited
across 23 districts of Scotland in 1984 to 1987,8,9 with those
of Scottish MONICA aged 25 to 64 years from Edinburgh and
North Glasgow 1986; and North Glasgow 1989, 1992 (25 to
75 years), and 1995.10 With ethical committee approval,
participants gave written consent for the study, completed a
self-administered health record, including the reporting of
chest pain11 and leg pain on exercise12; they attended
recruitment survey clinics at which they had physical
measurements including brachial but not ankle blood pres-
sure; they each had a 12-lead resting ECG, categorized using
the Minnesota code13; gave blood, and consented to follow-up
through their medical records. SHHEC received extra
resources for intensive study of smoking and its biochemistry,
with a detailed questionnaire, and measurement of expired air
carbon monoxide, serum thiocyanate, and serum cotinine.14
Each of the 23 SHHS districts was visited twice in different
seasons.8 North Glasgow MONICA involved 4 independently
sampled population surveys at 3-year intervals.
Baseline cardiovascular disease (CVD) was identiﬁed by
self-report and documented hospital discharge diagnoses. It
included any diagnosis of CHD; cerebrovascular disease,
including transient ischemic attacks; heart failure and PAD,
plus major Q waves on the recruitment ECG. Mortality and
hospital inpatient episodes were followed by periodic national
record linkage. That was used to the end of 2005 in the
derivation of the Scottish ASSIGN risk score, a combined
cardiovascular end point, used here for comparison with the
new prediction models.15 Follow-up to the end of 2009
increased numbers of events, allowing study of CHD and PAD
as separate end points.
Exclusions and End Points
After exclusion of baseline CVD, any CHD or PAD diagnosis
during follow-up in any of the multiple cause ﬁelds of hospital
diagnoses or of death certiﬁcation qualiﬁed as an end point
event; the ﬁrst recorded event in each category ended follow-
up for that item. CHD was deﬁned as International Classiﬁ-
cation of Diseases Edition 9 (ICD 9) 410 to 414; (ICD 10) I20
to I25, while PAD was (ICD 9) 440.2, 443.9, 250.6; (ICD 10)
I70.2, I73.9, E10.5, E11.5, E12.5, E13.5, E14.5.
Laboratory Procedures
After venipuncture, blood for serum was left to coagulate up to
4 hours. Separated serum was stored at 4°C pending labora-
tory testing for recruitment biomarkers 1 to 3 days later in a
dedicated Dundee laboratory. Plasma was stored at 40°C
and analyzed for ﬁbrinogen in Glasgow16 but archived long
term in only a minority, whereas aliquots of serum were
generally biobanked long term at40°C and assayed as part of
the MORGAM Biomarker study, and BiomarCaRE, in laborato-
ries in Mainz and Hamburg between 2008 and 2014.17,18
Statistical Analyses
Participants were excluded if below age 30 or with existing
CVD (see above). Baseline characteristics of the study
population were analyzed overall and separately for men
and women, without regard to age or missing values.
Hazard ratios were then calculated by the Cox proportional
hazards method, after proportionality for key risk factors
had been conﬁrmed, ﬁrst adjusted for age and sex, and
then multiply adjusted for all 9 variables in the ASSIGN15
score. These are age, sex, family history of coronary heart
disease, socioeconomic status (from the postcode-derived
Clinical Perspective
What Is New?
• Large prospective studies, with limited risk-factor measure-
ments, may conclude that risk factors for peripheral arterial
disease (PAD) and coronary heart disease are the same.
• The Scottish Heart Health Extended Cohort (SHHEC) study
involved measurement of 45 factors with follow-up of
15 737 men and women over 20 years, generating 3098
cases of coronary heart disease and 499 cases of PAD,
enabling detailed comparison of predictors.
What Are the Clinical Implications?
• Despite overlap, predictors differed for PAD and coronary
heart disease. Total cholesterol, dominant in coronary heart
disease, was not predictive in PAD, where inﬂammatory
markers dominated.
• Diabetes mellitus was a powerful predictor of PAD but not
the most common cause.
• Tobacco smoking was the predominant cause of PAD,
evidenced both by self-report and several biochemical
measures of smoking, which reinforced prediction.
• A 3.2% incidence of clinical cases, over 20 years, does not
warrant a separate PAD predictive score in healthy subjects,
compared with predicting cardiovascular disease as a
whole.
• Differing predictors suggest mechanisms for future inter-
ventions.
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deprivation score, the Scottish Index of Multiple Depriva-
tion),15 diabetes mellitus, cigarette equivalent dose (incor-
porating self-reported cigarette consumption, plus
equivalent for pipe and cigar smokers and smoking
deceivers using their biochemical results),14 systolic blood
pressure, total cholesterol and high-density lipoprotein
(HDL) cholesterol. For the hazard-ratio calculations, multiple
imputation was used for missing values, by chained equations
with 5 multiple imputation data sets.19 Variables were then
reduced in number to produce 2 parsimonious models for
prediction of each end point. First, the factors were given an
equal start whether or not they were ASSIGN risk factors, and
stepwise regression was used to produce a “best model,”
retaining only those that remained signiﬁcantly predictive at
the 5% level when mutually adjusted. In the second “extended
ASSIGN model,” ASSIGN risk factors were forced to remain in
while the other factors competed for inclusion. C-statistics and
net reclassiﬁcation improvements, the latter using 10% and
20% 10-year risk thresholds, were used to estimate the
resulting changes in prediction of the 2 end points with these 2
models, in comparison with the 9 factors previously used in
ASSIGN.20-22 Analyses were conducted using StataSE 12
(Statacorp, College Station, TX), and R version 3.3.0 (R
Foundation, Vienna, Austria). Statistical testing was done for
main analyses with the sexes combined, but sex-speciﬁc
results were also calculated.
Results
Numbers Involved
Exclusion from the 18 107 SHHEC participants of those
below age 30 (750), and/or those with CVD at recruitment
(1623, with 3 overlapping), reduced this to 15 737. Many
baseline risk factors were recorded in all of these, but
shortage of serum, starting with failed or refused venipunc-
ture, was a limiting factor. Completeness ranged from 90.1%
(uric acid) down to 69.8% (cotinine) for initial Dundee assays.
For biobanked serum sent to Germany, it was 81.8%
(apolipoprotein A) down to 66.8% (NT-pro-BNP) as serum
became progressively depleted.
Baseline Status of Participants and Numbers of
End Point Events During Follow-Up
Baseline levels of risk factors derived from the health
questionnaire and recruitment survey clinic, from biomarkers
measured then, and in archived serum decades later, are shown
in Table 1 along with numbers of completed measurements.
The cohort was followed to the end of 2009 from a decade
(1984 to 1995) during which Scotland at times had the world’s
highest coronary heart disease mortality in both sexes. Mean
follow-up of the 15 737 study participants was 19.9 years; of the
11 706 who remained alive at December 31, 2009, it was
Table 1. Baseline Variable Summary Statistics: SHHEC Participants by Sex, Aged ≥30, and Free of CVD
Values Obtained Men Women All
Number of participants 15 737 7552 8185 15 737
Personal
Age† 15 737 49.0 (8.3) 49.0 (8.3) 49.0 (8.3)
Sex,† male% 15 737 100 0 52.0.
Years of education 15 396 11.2 (2.8) 11.1 (2.5) 11.1 (2.6)
Family history of CHD,† % 15 737 25.5 31.8 28.8
SIMD-socioeconomic score† 15 737 28.0 (21.9) 28.6 (22.0) 28.3 (21.9)
ASSIGN cardiovascular risk score† 13 444 14.8 (10.6) 9.5 (9.9) 12.1 (10.6)
Smoking
Current tobacco smoker, % 15 737 51.6 40.2 45.7
Cigarettes equivalent,† cigs/d 15 737 9.1 (11.9) 6.6 (9.6) 7.8 (10.83)
Expired carbon monoxide, ppm 15 257 10.6 (12.5) 9.0 (11.5) 9.8 (12.0)
Thiocyanate, lmol/L* 13 738* 57.8 (1.99) 58.4 (1.98) 58.1 (1.98)
Cotinine, ng/mL 10 984 128 (171) 103 (152) 115 (162)
Physical measurements
Height, m 15 729 1.73 (0.07) 1.60 (0.06) 1.66 (0.09)
Weight, kg 15 727 77.9 (12.5) 65.9 (12.6) 71.6 (13.9)
Continued
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Table 1. Continued
Values Obtained Men Women All
Body mass index, kg/m2 15 725 26.0 (3.7) 25.8 (4.8) 25.9 (4.3)
Waist circumference, cm 4061 92.2 (11.6) 80.5 (12.2) 85.9 (13.2)
Waist/hip ratio 4061 0.92 (0.078) 0.79 (0.071) 0.85 (0.096)
SBP,† mm Hg 15 729 134.0 (19.4) 130.5 (21.1) 132.1 (20.4)
DBP, mm Hg 15 729 83.4 (12.0) 79.6 (11.9) 81.4 (12.1)
Pulse pressure, mm Hg 15 729 50.6 (14.1) 50.8 (15.1) 50.7 (14.6)
Pulse rate, bpm 15 661 76.5 (13.3) 78.6 (12.3) 77.6 (12.9)
Diabetes mellitus
Diabetes mellitus,† % 15 737 1.6 1.4 1.5
Glucose, mmol/L (nonfasting) 12 837 5.17 (1.54) 4.92 (1.36) 5.04 (1.46)
Insulin, lU/mL (nonfasting)‡ 12 281 11.2 (13.2) 8.52 (9.60) 9.83 (11.6)
C-Peptide, mg/mL*‡ 12 365 (13)* 2.41 (1.92) 2.14 (1.82) 2.27 (1.90)
Lipids
Total cholesterol,† mmol/L 14 172 6.23 (1.16) 6.40 (1.30) 6.32 (1.24)
HDL-cholesterol,† mmol/L 13 460 1.35 (0.37) 1.63 (0.43) 1.49 (0.42)
Non-HDL-cholesterol, mmol/L 13 459 4.88 (1.14) 4.78 (1.21) 4.88 (1.18)
Triglycerides, mmol/L* 14 158 1.91 (1.77) 1.41 (1.69) 1.64 (1.76)
LDL-cholesterol, mmol/L‡ 10 833 2.65 (1.27) 2.75 (1.19) 2.70 (1.16)
Apolipoprotein A, g/L‡ 12 867 1.49 (0.26) 1.64 (0.30) 1.57 (0.29)
Apolipoprotein B, g/L‡ 12 866 1.18 (0.30) 1.13 (0.32) 1.15 (0.31)
Lipoprotein (a), mg/dL*‡ 12 773 (88)* 9.55 (3.89) 11.81 (3.38) 10.64 (3.64)
Inflammatory
hsC-reactive protein, mg/L*‡ 12 847 1.53 (2.99) 1.27 (3.10) 1.39 (3.06)
Fibrinogen, g/L 13 101 2.75 (0.80) 2.86 (0.81) 2.81 (0.81)
Homocysteine, lmol/L‡ 12 843 16.0 (6.6) 14.0 (5.7) 14.9 (6.2)
Ferritin, lmol/L*‡ 12 319 (22)* 103.0 (2.64) 38.0 (2.97) 62.0 (3.14)
Cardiac
hsTroponin I, pg/mL*‡ 11 527 (427)* 3.76 (2.60) 2.25 (3.80) 2.97 (3.29)
NT-pro-BNP, pg/mL*‡ 10 507 31.7 (2.94) 61.5 (2.45) 44.7 (2.83)
Diet related
25-Hydroxyvitamin D raw, nmol/L‡ 11 603 44.3 (22.7) 39.2 (19.7) 41.6 (21.3)
25-Hydroxyvitamin D adj, nmol/L‡ 11 603 44.0 (19.3) 39.4 (17.9) 41.6 (18.7)
Vitamin B12, pg/mL
‡ 12 355 425 (180) 423 (191) 424 (186)
c-Glutamyl transferase, units/L* 12 835 31.4 (1.92) 18.5 (1.79) 24.1 (1.96)
Renal related
Uric acid, mmol/L 14 178 320 (66) 243 (62) 281 (75)
Creatinine, mmol/L 11 837 95.9 (12.9) 81.4 (11.0) 88.6 (14.0)
Cystatin-C, mg/L‡ 12 868 0.760 (0.143) 0.716 (0.165) 0.738 (0.156)
Missing values are omitted. Percentages are shown for categorical factors. Arithmetic means and standard deviations are shown for continuous variables with some exceptions.*CHD
indicates coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HDL, high-density lipoprotein; SBP, systolic blood pressure; SHHEC, Scottish Heart Health
Extended Cohort; SIMD, Scottish Index of Multiple Deprivation.
*Geometric means and standard deviations because of positive skew. For these geometric calculations any 0 values (number in parentheses) are set to 0.01 units.
†
ASSIGN risk score factor.
‡Assayed in the MORGAM/BiomarCaRE project after long-term storage of serum at 40°C.
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22.0 years. Participants from the original 15 737 later recorded
as developing any death certiﬁcate or hospital inpatient diagnosis
of CHD numbered 3098 (19.7%), and of PAD 499 (3.2%). Of the
latter, 285 (57%) developed both pathologies—CHD ﬁrst in 143,
PAD ﬁrst in 97, and both together in 45.
Prediction From Symptom Questionnaires and
the ECG
At recruitment, of the 15 737 without diagnosed CVD, 860
(5.5%) were chest pain positive to the Rose “angina”
questionnaire,11 of whom 279 later developed clinical CHD
and 37 developed PAD; 335 (2.1%) were positive for the
Edinburgh leg pain “claudication” questionnaire,12 of whom
104 developed CHD and 47 developed PAD (Table 2).
Symptom questionnaires anticipated 1 in 11 related events
over 20 years. Chest pain questionnaire positive responses
had a 1.7-fold increased CHD incidence over negatives; leg
pain positives 4.8-fold PAD incidence over negatives but
developed numerically more cases of CHD than PAD.
The 12-lead ECG, coded to the Minnesota code, was
classiﬁed in 1165 (7.4%) as “possible ischemia” for minor Q
waves and ST and T wave ﬁndings.13 These ﬁndings
anticipated 382 clinical CHD, and 58 PAD cases—one in 8
of CHD and of PAD, marginally more than the questionnaires.
Positives had a 1.8-fold increased incidence of CHD over
negatives and a 1.6-fold increase for PAD (Table 2).
Hazard Ratios
Table 3 shows the Cox proportional hazards ratios (HRs) for
CHD and for PAD for the 45 individual, derived, or composite
factors from Table 1, initially adjusted by age and sex, for the
sexes combined, with missing values imputed. Then this is
repeated with additional adjustment for the remaining
ASSIGN factors, after omitting these factors and their
derivatives, leaving 33 factors. To help comparison, recipro-
cals of hazard ratios are used in the few variables where that
for CHD is <1.0 (for example HDL-cholesterol). Sex-speciﬁc
results are given in Table 4.
In Table 3 almost all HRs are initially signiﬁcant at 5%: 41
out of 45 for CHD, and 38 out of 45 for PAD despite smaller
numbers and consequently bigger conﬁdence intervals.
Comparison of the hazard ratios in Table 3 between PAD and
CHD, shows PAD HRs initially higher in 30, signiﬁcantly so in 22.
This applies to 5 of the 9 ASSIGN factors, speciﬁcally to age,
Table 2. Sensitivity, Speciﬁcity, and Predictive Value for Baseline Symptom Questionnaires and ECG Ischemia Versus 20-Year
Disease Outcomes, Sexes Combined
See Key
Rose Angina
Questionnaire
Edinburgh Claudication
Questionnaire
Electrocardiographic “Possible
Ischemia” (Minnesota Code)
End Point CHD PAD CHD PAD CHD PAD
True positive N a 279 37 104 47 382 58
False positive N b 581 823 231 288 783 1107
False negative N c 2819 462 2994 452 2716 441
True negative N d 12 058 14 415 12 408 14 950 11 856 14 131
Sensitivity, % a9100/(a+c) 9.0 7.4 3.4 9.4 12.3 11.6
Specificity, % d9100/(b+d) 95.4 94.6 98.2 98.1 93.8 92.7
Positive predictive value, % a9100/(a+b) 32.4 4.3 31.0 14.0 32.8 5.0
Negative predictive value, % d9100/(c+d) 81.1 96.9 80.6 97.1 81.4 97.0
Prediction ratio ppv/(100npv) 1.7 1.4 1.6 4.8 1.8 1.6
CHD indicates coronary heart disease; PAD, peripheral arterial disease.
Key
Disease
Positive Negative
Test Positive a b a+b
Negative c d c+d
a+c b+d All 15 737
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Table 4. Hazard Ratios and 95% Conﬁdence Limits by Individual Factors for CHD and PAD, Adjusted First for Age and Then
Additionally for ASSIGN Factors (Which are Excluded), for the Sexes Separately
Adjusted for Age Coronary Heart Disease Peripheral Arterial Disease
Men 1847 Women 1251 Men 291 Women 208
Personal
Age† 1.57 (1.50; 1.65)* 1.84 (1.73; 1.95)* 1.75 (1.54; 1.99)* 1.96 (1.69; 2.28)*
Years of education R 1.16 (1.11; 1.22)* 1.32 (1.23; 1.43)* R 1.27 (1.11; 1.45)* 1.35 (1.12; 1.61)*
Family history CHD† 1.45 (1.31; 1.60)* 1.69 (1.51; 1.89)* 1.57 (1.23; 2.01)* 1.48 (1.12; 1.95)*
SIMD score (SES)† 1.18 (1.12; 1.23)* 1.30 (1.23; 1.37)* 1.48 (1.33; 1.65)* 1.56 (1.38; 1.77)*
ASSIGN CV risk score† 1.44 (1.39; 1.50)* 1.50 (1.44; 1.56)* 1.76 (1.62; 1.92)* 1.79 (1.66; 1.93)*
Smoking
Current smoker Y/N 1.60 (1.46; 1.76)* 1.86 (1.66; 2.07)* 3.96 (3.01; 5.21)* 7.08 (5.07; 9.88)*
Cigs/day equivalent† 1.29 (1.24; 1.34)* 1.40 (1.33; 1.48)* 1.68 (1.54; 1.82)* 2.01 (1.85; 2.19)*
Expired CO 1.26 (1.22; 1.31)* 1.28 (1.21; 1.34)* 1.61 (1.49; 1.73)* 1.88 (1.73; 2.04)*
Thiocyanate 1.28 (1.22; 1.34)* 1.30 (1.22; 1.37)* 2.05 (1.81; 2.33)* 2.44 (2.09; 2.85)*
Cotinine 1.33 (1.27; 1.38)* 1.37 (1.30; 1.44)* 1.76 (1.59; 1.95)* 2.09 (1.87; 2.34)*
Physical
Height R 1.15 (1.08; 1.22)* 1.28 (1.19; 1.41)* R 1.18 (1.01; 1.37)* 1.20 (0.98; 1.49)
Weight 1.14 (1.08; 1.20)* 1.21 (1.14; 1.28)* 0.93 (0.81; 1.07) 1.15 (0.99; 1.33)
Body mass index 1.24 (1.17; 1.30)* 1.24 (1.18; 1.29)* 0.99 (0.86; 1.14) 1.17 (1.04; 1.31)*
Waist circumference. 1.27 (1.19; 1.36)* 1.36 (1.27; 1.45)* 1.09 (0.93; 1.29) 1.37 (1.16; 1.61)*
Waist-to-hip ratio 1.16 (1.09; 1.22)* 1.27 (1.18; 1.37)* 1.14 (0.98; 1.33) 1.42 (1.17; 1.71)*
Systolic BP† 1.23 (1.18; 1.29)* 1.26 (1.19; 1.32)* 1.47 (1.33; 1.63)* 1.44 (1.28; 1.61)*
Diastolic BP 1.19 (1.14; 1.25)* 1.19 (1.13; 1.26)* 1.18 (1.06; 1.32)* 1.12 (0.97; 1.29)
Pulse pressure 1.05 (1.02; 1.08)* 1.05 (1.02; 1.08)* 1.09 (1.05; 1.14)* 1.08 (1.03; 1.12)*
Pulse rate 1.09 (1.05; 1.13)* 1.09 (1.05; 1.13)* 1.23 (1.14; 1.34)* 1.23 (1.14; 1.34)*
Diabetes
Diabetes mellitus† 2.26 (1.72; 2.96)* 3.24 (2.42; 4.32)* 6.31 (4.08; 9.76)* 7.39 (4.55; 12.00)*
Glucose (non-fasting) 1.09 (1.04; 1.13)* 1.15 (1.09; 1.21)* 1.24 (1.17; 1.32)* 1.23 (1.13; 1.34)*
Insulin (non-fasting) 1.07 (1.03; 1.10)* 1.15 (1.11; 1.19)* 1.06 (0.96; 1.16) 1.20 (1.12; 1.29)*
C-peptide 1.05 (0.98; 1.13)* 1.01 (0.91; 1.12) 1.00 (0.86; 1.17) 0.98 (0.81; 1.18)
Lipids
Total cholesterol† 1.30 (1.24; 1.36)* 1.23 (1.16; 1.29)* 1.13 (0.99; 1.28) 1.23 (1.07; 1.41)*
HDL cholesterol† R 1.15 (1.09; 1.20)* 1.20 (1.14; 1.27)* R 1.02 (0.91; 1.15) 1.37 (1.15; 1.64)*
Non-HDL cholesterol 1.36 (1.30; 1.43)* 1.31 (1.24; 1.38)* 1.14 (1.00; 1.28)* 1.37 (1.20; 1.56)*
LDL cholesterol 1.13 (1.08; 1.18)* 1.15 (1.09; 1.22)* 1.10 (0.98; 1.24) 1.11 (0.98; 1.26)
Triglycerides 1.30 (1.23; 1.36)* 1.45 (1.36; 1.55)* 1.26 (1.12; 1.42)* 1.85 (1.58; 2.18)*
Apolipoprotein A R 1.18 (1.12; 1.25)* 1.27 (1.19; 1.35)* R 1.20 (1.04; 1.39)* 1.28 (1.05; 1.54)*
Apolipoprotein B 1.38 (1.31; 1.46)* 1.29 (1.24; 1.35)* 1.28 (1.15; 1.44)* 1.35 (1.23; 1.50)*
Lipoprotein (a) 1.01 (0.97; 1.06) 1.10 (0.98; 1.24) 1.12 (0.94; 1.34) 1.59 (0.97; 2.61)
Inflammatory
hsC-reactive protein 1.32 (1.24; 1.40)* 1.47 (1.37; 1.58)* 1.73 (1.53; 1.95)* 1.95 (1.70; 2.24)*
Fibrinogen 1.17 (1.12; 1.22)* 1.20 (1.13; 1.27)* 1.32 (1.23; 1.42)* 1.29 (1.15; 1.44)*
Homocysteine 1.16 (1.11; 1.21)* 1.14 (1.06; 1.22)* 1.20 (1.09; 1.32)* 1.22 (1.08; 1.39)*
Continued
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Table 4. Continued
Adjusted for Age Coronary Heart Disease Peripheral Arterial Disease
Men 1847 Women 1251 Men 291 Women 208
Ferritin 1.04 (0.98; 1.11) 1.12 (1.01; 1.23)* 1.21 (0.97; 1.50) 1.26 (0.83; 1.91)
Cardiac
hsTroponin I 1.68 (1.39; 1.98)* 1.57 (1.41; 1.73)* 2.13 (1.12; 3.14)* 1.64 (1.04; 2.24)*
NT-pro-BNP 1.23 (1.17; 1.30)* 1.27 (1.17; 1.38)* 1.44 (1.27; 1.63)* 1.32 (1.07; 1.64)*
Diet related
25OH-vitamin D raw R 1.19 (1.10; 1.28)* 1.16 (1.09; 1.25)* R 1.67 (1.43; 1.96)* 1.52 (1.14; 2.00)*
25OH-vitamin D adj R 1.16 (1.09; 1.25)* 1.20 (1.11; 1.30)* R 1.61 (1.37; 1.89)* 1.59 (1.16; 2.17)*
Vitamin B12 1.03 (0.97; 1.09) 1.00 (0.94; 1.06) 1.07 (0.95; 1.21) 1.03 (0.90; 1.18)
Gamma glutamyl TF 1.17 (1.11; 1.23)* 1.27 (1.19; 1.35)* 1.32 (1.18; 1.48)* 1.54 (1.36; 1.76)*
Renal related
Uric Acid 1.02 (0.97; 1.09) 1.19 (1.11; 1.27)* 0.91 (0.78; 1.06) 1.21 (1.03; 1.42)*
Creatinine 0.99 (0.93; 1.06) 1.05 (0.97; 1.12) 0.99 (0.85; 1.15) 1.02 (0.82; 1.26)
Cystatin -C 1.20 (1.14; 1.26)* 1.14 (1.12; 1.17)* 1.26 (1.15; 1.40)* 1.17 (1.12; 1.23)*
Adjusted Additionally for ASSIGN Variables (Which are Omitted)
Coronary Heart Disease Peripheral Artery Disease
Men 1847 Women 1251 Men 291 Women 208
Personal
Years of education R 1.10 (1.04; 1.16)* 1.15 (1.08; 1.23)* R 1.11 (0.96; 1.28) 1.04 (0.87; 1.25)
Smoking
Expired CO 1.09 (1.03; 1.14)* 1.08 (1.01; 1.15)* 1.33 (1.20; 1.47)* 1.56 (1.40; 1.73)*
Thiocyanate 1.05 (0.99; 1.12) 1.07 (1.00; 1.15)* 1.63 (1.38; 1.92)* 1.94 (1.62; 2.32)*
Cotinine 1.18 (1.11; 1.27)* 1.19 (1.12; 1.28)* 1.42 (1.22; 1.66)* 1.72 (1.48; 1.99)*
Physical
Height R 1.08 (1.01; 1.14)* 1.16 (1.08; 1.27)* R 1.03 (0.89; 1.22) 1.00 (0.81; 1.23)
Weight 1.09 (1.04; 1.15)* 1.12 (1.05; 1.19)* 0.91 (0.80; 1.04) 1.03 (0.89; 1.19)
Body mass index 1.14 (1.09; 1.21)* 1.14 (1.09; 1.20)* 0.90 (0.79; 1.04) 1.02 (0.91; 1.15)
Waist circumference 1.17 (1.08; 1.26)* 1.20 (1.11; 1.30)* 0.97 (0.82; 1.15) 1.11 (0.93; 1.33)
Waist-to-hip ratio 1.07 (0.99; 1.16) 1.12 (1.02; 1.23)* 1.03 (0.87; 1.23) 1.17 (0.91; 1.51)
Diastolic BP 1.06 (1.00; 1.12)* 1.03 (0.97; 1.10) 0.91 (0.81; 1.03) 0.88 (0.78; 1.00)*
Pulse pressure R 1.11 (1.00; 1.23)* 1.09 (0.99; 1.20) R 0.99 (0.91; 1.09) 1.03 (0.94; 1.12)
Pulse rate 1.00 (0.96; 1.03) 1.00 (0.96; 1.03) 1.06 (0.97; 1.15) 1.06 (0.97; 1.15)
Diabetes
Glucose (non-fasting) 1.03 (0.99; 1.07) 1.08 (1.03; 1.13)* 1.19 (1.10; 1.28)* 1.14 (1.04; 1.24)*
Insulin (non-fasting) 1.05 (1.01; 1.08)* 1.09 (1.04; 1.14)* 1.04 (0.93; 1.16) 1.09 (0.98; 1.20)
C-peptide 1.03 (0.98; 1.10) 1.01 (0.94; 1.08) 1.05 (0.93; 1.20) 1.01 (0.90; 1.13)
Lipids
LDL cholesterol R 1.00 (0.94; 1.05) 1.02 (0.95; 1.09) R 1.00 (0.88; 1.15) 1.04 (0.90; 1.20)
Triglycerides 1.12 (1.06; 1.18)* 1.15 (1.07; 1.24)* 1.08 (0.95; 1.22) 1.41 (1.19; 1.67)*
Apolipoprotein A R 1.11 (1.04; 1.18)* 1.18 (1.08; 1.27)* R 1.11 (0.93; 1.32) 1.12 (0.92; 1.37)
Apolipoprotein B 1.21 (1.11; 1.31)* 1.10 (1.02; 1.18)* 1.14 (0.96; 1.36) 1.15 (0.98; 1.36)
Continued
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socioeconomic status, smoking (but also all measures of smoking
biochemistry), systolic blood pressure (but also pulse pressure
and pulse rate), diabetes mellitus, and also nonfasting glucose,
triglycerides, high-sensitivity C-reactive protein (hsCRP), ﬁbrino-
gen, NT-pro-BNP, 25-hydroxyvitamin D (25OHD), and c-glutamyl
transferase. However, among the 8 lipid variables, only the HR for
triglycerides is signiﬁcantly different in this analysis, although that
for lipoprotein (a) emerges in later analyses. In only 13 variables
were HRs for CHD more extreme than those for PAD, 2
signiﬁcantly so: weight and body mass index (BMI).
After adjustment for ASSIGN variables in Table 3, there are 24
remaining signiﬁcant factors for CHD out of 33, and the number
for PAD is 14. The HRs remain signiﬁcantly increased in PAD
compared with CHD for the 3 measures of smoke inhalation,
nonfasting glucose, hsCRP, ﬁbrinogen, 25OHD, and c-glutamyl
transferase. None of the 5 remaining lipids shows a signiﬁcant
difference. Adjustment for ASSIGN variables has reversed the HR
gradient for pulse pressure, LDL-cholesterol, and B12, now shown
as the reciprocal, but not signiﬁcantly different between the end
points. There are10 factors forwhichCHDHRsaremore extreme,
weight and BMI signiﬁcantly so, with waist circumference now
added, and diastolic blood pressure anomalous—the HRs for the
2 diseases are both signiﬁcant, but signiﬁcantly different, on
either side of 1.00 (see Discussion).
Parsimonious Modeling
Stepwise elimination of factors for parsimoniousmodelswasnot
contingent on analyses for Table 3, as almost every factor was
entered anew into these calculations (the exception was non-
HDL-cholesterol, removed because it was derived by subtrac-
tion, causing unacceptable collinearity with total cholesterol). In
the Figure factors are displayed for the bestmodels for CHD and
PAD in descending order of hazard ratios for both sexes
combined, using the reciprocal for those <1.0 and separating
binary and continuous variables. CHD has 20 factors in the best
model, and PAD 16 despite many fewer end points. Again PAD
has higher HRs than CHD, with wider conﬁdence intervals.
However, the adjustment of each HR for all others in the model
means that individual HRs should not now be compared directly.
Data for this ﬁgure, for sex-speciﬁc results, and also for the
extended ASSIGN models are available in Table 5.
Table 4. Continued
Adjusted Additionally for ASSIGN Variables (Which are Omitted)
Coronary Heart Disease Peripheral Artery Disease
Men 1847 Women 1251 Men 291 Women 208
Lipoprotein (a) 1.01 (0.97; 1.05) 1.02 (0.93; 1.12) 1.13 (0.95; 1.33) 1.47 (0.89; 2.41)
Inflammatory
hsC-reactive protein 1.17 (1.08; 1.26)* 1.28 (1.19; 1.38)* 1.41 (1.23; 1.62)* 1.57 (1.35; 1.82)*
Fibrinogen 1.09 (1.04; 1.14)* 1.09 (1.02; 1.16)* 1.21 (1.10; 1.34)* 1.12 (0.99; 1.27)
Homocysteine 1.10 (1.05; 1.14)* 1.05 (0.98; 1.13) 1.06 (0.96; 1.17) 1.08 (0.94; 1.25)
Ferritin 1.01 (0.95; 1.07) 1.03 (0.95; 1.12) 1.08 (0.90; 1.31) 1.07 (0.80; 1.43)
Cardiac
hsTroponin I 1.33 (1.14; 1.41)* 1.28 (1.16; 1.40)* 1.51 (0.79; 2.23) 1.24 (0.85; 1.63)
NT-pro-BNP 1.21 (1.15; 1.27)* 1.23 (1.13; 1.34)* 1.27 (1.13; 1.44)* 1.20 (0.97; 1.49)
Diet related
25OH-vitamin D raw R 1.05 (0.99; 1.12) 1.04 (0.96; 1.11) R 1.35 (1.12; 1.61)* 1.16 (0.89; 1.54)
25OH-vitamin D adj. R 1.06 (1.00; 1.14)* 1.02 (0.94; 1.09) R 1.28 (1.09; 1.52)* 1.20 (0.89; 1.61)
Vitamin B12 R 1.00 (0.93; 1.05)* 1.03 (0.97; 1.10) R 0.97 (0.85; 1.10) 0.99 (0.86; 1.14)
Gamma glutamyl TF 1.05 (1.00; 1.11)* 1.11 (1.03; 1.20)* 1.13 (1.00; 1.28)* 1.30 (1.13; 1.49)*
Renal related
Uric Acid 1.02 (0.96; 1.08) 1.08 (1.01; 1.16)* 0.96 (0.82; 1.13) 1.14 (0.96; 1.34)
Creatinine 1.03 (0.97; 1.10) 1.03 (0.96; 1.10) 1.09 (0.97; 1.22) 1.06 (0.87; 1.30)
Cystatin-C 1.14 (1.09; 1.20)* 1.12 (1.07; 1.16)* 1.18 (1.07; 1.30)* 1.18 (1.10; 1.27)*
These are sex-speciﬁc results equivalent to the sexes combined results in Table 3. Missing values are imputed using multiple imputation by chained equation (m=5, i=10). Hazard ratios are
per standard deviation for continuous variables, some are log transformed (see Table 1). R-Hazard ratios <1.0 are converted to their reciprocal to facilitate comparison (using CHD both
sexes as the criterion from Table 3).
*Hazard ratios signiﬁcant at 5%. †ASSIGN risk score factors.
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C-Statistic and Net Reclassiﬁcation Improvement
Finally the c-statistic and net reclassiﬁcation improvement
(NRI) were calculated to see what difference was made in
speciﬁc prediction of CHD and PAD, using the new models as
against the historical ASSIGN cardiovascular risk factors (see
Table 6). The original 9 ASSIGN risk factors gave high c-
statistics in both CHD and PAD, paradoxically higher in PAD,
although it was a minority contributor in numbers of end
points to the original derivation of the ASSIGN score.15 The
new models showed improved c-statistics and substantial
NRIs for both end points, considerably more so for PAD.
Differences between the “best” and the “extended ASSIGN”
models were modest and even inconsistent.
The ﬁnal pattern of risk factors in the “best” models differs
from the original ASSIGN panel in both CHD and PAD, with the
recruitment of new factors and the downgrading of some
classic factors, and there are noteworthy differences between
all CHD and all PAD cases in these analyses, despite the 57%
overlap of cases during follow-up.
CHD
Binary
Diabetes mellitus
Sex: male/female
Family history of CHD
Continuous
Age
Total cholesterol
hsTroponin I
NT-pro-BNP
Cotinine
R-Apolipoprotein-A
Waist circumference
R-Height
hsC-reactive protein
Systolic blood pressure
SIMD  score (SES)
R-Years of education
Cigarettes/day
R-LDL-cholesterol
Cystatin-C
Homocysteine
Insulin
PAD
Binary
Diabetes mellitus
Tobacco smoker
Sex: male/female
Family history of CHD
Continuous
Age
hsC-reactive protein
Systolic blood pressure
Expired carbon monoxide
Cotinine
SIMD  score (SES)
Lipoprotein (a)
R-25OHD-adjusted
NT-pro-BNP
Glucose
Triglycerides
Cystatin-C
Outcome/variable
2.21 (1.79, 2.71)
1.99 (1.72, 2.13)
1.42 (1.32, 1.53)
1.38 (1.32, 1.44)
1.31 (1.25, 1.38)
1.21 (1.11, 1.31)
1.21 (1.15, 1.27)
1.19 (1.12, 1.26)
1.16 (1.11, 1.22)
1.15 (1.06, 1.25)
1.14 (1.08, 1.19)
1.13 (1.06, 1.19)
1.12 (1.08, 1.16)
1.09 (1.05, 1.13)
1.08 (1.03, 1.12)
1.07 (1.02, 1.14)
1.06 (1.01, 1.12)
1.06 (1.02, 1.09)
1.06 (1.02, 1.10)
1.05 (1.02, 1.09)
3.38 (2.23, 5.13)
2.15 (1.58, 2.93)
1.59 (1.30, 1.96)
1.44 (1.20, 1.74)
1.62 (1.45, 1.81)
1.42 (1.27, 1.59)
1.30 (1.19, 1.42)
1.24 (1.13, 1.38)
1.24 (1.06, 1.45)
1.24 (1.13, 1.36)
1.21 (1.04, 1.42)
1.20 (1.03, 1.41)
1.19 (1.06, 1.34)
1.18 (1.11, 1.24)
1.16 (1.04, 1.29)
1.10 (1.02, 1.19)
ratio (95% CI)
Hazard
1 2 3 4
Figure. Ranking of hazard ratios (shown with 95% conﬁdence limits) for the best parsimonious predictive
models for 20-year incidence of coronary heart disease and peripheral arterial disease (sexes combined).
CHD indicates coronary heart disease; hs, high-sensitivity; NT-pro-BNP, N-terminal prohormone of brain
natriuretic peptide; PAD, peripheral arterial disease; R-, reciprocal of . . . ; SIMD, Scottish Index of Multiple
Deprivation score (socioeconomic status); 25OHD, 25-hydroxyvitamin D.
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Discussion
PAD, the Cardiovascular Iceberg
PAD is prevalent worldwide, causing serious morbidity and
contributing to the burden for health services associated with
the pandemics of cigarette smoking and diabetes mellitus,
with amputation a dreaded complication.1-5 It trails behind
CHD and stroke, the lion and tiger of CVD, as an identiﬁable
killer; like an iceberg, it mostly lacks visibility.
PAD causes arterial narrowing and a diminished ankle-to-
brachial bloodpressure index, (ABI). SoPAD isnowdeﬁnedas an
ABI of ≤0.9,5,23 which facilitates international research with
increasing prevalence and incidence compared to clinical
diagnosis.1 In SHHEC clinical incidence was 6 times greater
for CHD than PAD, but questionnaire positive prevalence results
at baseline were 2.6 times higher. ABI measurements were not
used, so their effect on comparative prevalence and incidence is
unknown.
The epidemiology of CHD is dominated by cohort studies,
following healthy participants for disease; PAD is dominated
by case-control studies from vascular clinics, follow-up of
diabetic populations, or screening studies involving ABI,
sometimes repeated.6,7 ABI suffers the problems of other
screening tools.24,25 In simultaneous assessment of disease
and risk factors, there is potential confusion of cause and
effect.26 Some large-cohort studies of PAD had a limited panel
of risk factors at recruitment and concluded that risk factors
for CHD and PAD are the same.1,27
Merits and Limitations of the Study
The advantages include these:
1. Cohort design, with random population sampling across
Scotland, covering classic and novel risk factors.
2. Twenty-year follow-up by national record linkage of
multiple-cause death certiﬁcation and hospital diagnoses
during an era of high incidence of CVD.
3. Measurement of additional biomarkers on all participants
after the end, using archived serum.
4. Prospective design minimizes both observer bias and
confusion of cause and effect.
The disadvantages are these:
1. Predictive factors were measured only once in each
participant.
2. Although 90.1% were linked to national disease records in
follow-up, unlinked participants could be persistently too
healthy to do so, or unhealthy failures.
3. The latest follow-up of end points was to the end of 2009,
but completion of laboratory work took until 2014, so
there was a gap, but 20 years was achieved.
4. Diagnoses of CHD and PAD were based on episodes,
numbering thousands, throughout Scotland, so indepen-
dent validation was impracticable.
5. Onset of CHD or PAD need not be followed by death or
hospital admission, or, if they were, probabilities of their
being recorded differ.
6. Deep-frozen serum, collected nonfasting, valid for many
assays, was inappropriate for others where fasting spec-
imens or plasma are preferable. For particular assays
frozen serum might deteriorate over 14 to 20 years.
7. Other risk factors might have been measured but were not
or were measured in only a minority of cases in SHHEC.
8. Some factors were recorded in SHHEC but not analyzed in
addition to the 45 listed (for example, food frequency,
alcohol, exercise, fatty acids).
9. Finally, the nature of multiple imputation is multiple
iteration.19 Repeating the procedure with different itera-
tions produces different answers through the play of
chance. Contrast the “best” and “extended ASSIGN”
models in the diseases (see Table 5).
Methodological Issues: HRs by Sex and in PAD
Versus CHD
HRs by sex for the same disease end point appear very similar;
most differences are small (see Table 4). Female HRs are
generally higher than male. The largest differences in HR occur
when both are high. When the 2 HRs are either side of 1.0, 1 or
both tend to lack statistical signiﬁcance. Largest differences by
sex in HR tend to diminishwhen simply age adjusted (Table 4) or
when additionally adjusted for ASSIGN variables (Table 4), and
even further in the parsimonious models after adjustment for
other factors in the model (Table 5). There appears not to be an
overall pattern except for the higher female than male values.
These can be explained by a similar mechanism to HRs for PAD
being greater than for CHD (next paragraph). The observed sex
differences do not test a previous, or suggest a new, hypothesis,
so they are reported without any testing of their differences
statistically. Such tests are reserved for the overall disease
differences with the sexes combined.
Table 3 shows numerous examples of variables where the
HR for PAD is signiﬁcantly higher than that for CHD. These
disease differences apply also to parsimonious modeling
(although HRs for individual factors are not strictly compara-
ble after mutual adjustment). Factors with lower HRs and
wider conﬁdence limits crossing 1.0 lack statistical signiﬁ-
cance, more likely in PAD with fewer end points. In the Figure
the lowest signiﬁcant HR is 1.10 for PAD but 1.05 for CHD.
But this is only a partial explanation.
HRs are ratios. The HR for tobacco smoking (Table 3) is 5.12
(4.14, 6.33) for PAD versus 1.70 (1.58, 1.83) for CHD and 6.76
(4.88, 9.35) versus 2.63 (2.16; 3.21) for diabetes mellitus.
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Table 5. Ranking of Hazard Ratios (shown with 95% Conﬁdence Limits) in Descending Order (Binary Then Continuous) for the Best
and Extended ASSIGN Models, for Coronary Heart Disease and Peripheral Arterial Disease
Coronary Heart Disease: Best Model
Men 1847 Women 1251 All 3098 Rank
Binary
Diabetes mellitus† 2.15 (1.63; 2.83) 2.19 (1.59; 3.02) 2.21 (1.79; 2.71) 1
Sex: male/female† 1.99 (1.72; 2.13) 2
Family history of CHD† 1.35 (1.22; 1.49) 1.52 (1.36; 1.70) 1.42 (1.32; 1.53) 3
Continuous
Age† 1.34 (1.26; 1.42) 1.48 (1.37; 1.60) 1.38 (1.32; 1.44) 1
Total cholesterol† 1.37 (1.28; 1.46) 1.23 (1.14; 1.32) 1.31 (1.25; 1.38) 2
hsTroponin I 1.19 (1.03; 1.35) 1.23 (1.12; 1.34) 1.21 (1.11; 1.31) 3
NT-pro-BNP 1.22 (1.15; 1.29) 1.21 (1.11; 1.31) 1.21 (1.15; 1.27) 3
Cotinine 1.20 (1.11; 1.30) 1.16 (1.06; 1.28) 1.19 (1.12; 1.26) 5
R-Apolipoprotein-A 1.15 (1.09; 1.22) 1.18 (1.10; 1.25) 1.16 (1.11; 1.22) 6
Waist circumference 1.17 (1.05; 1.30) 1.11 (1.02; 1.21) 1.15 (1.06; 1.25) 7
R-height 1.12 (1.04; 1.19) 1.16 (1.06; 1.27) 1.14 (1.08; 1.19) 8
hsC-reactive protein 1.08 (1.00; 1.17) 1.19 (1.09; 1.31) 1.13 (1.06; 1.19) 9
Systolic blood pressure† 1.13 (1.08; 1.19) 1.09 (1.03; 1.16) 1.12 (1.08; 1.16) 10
SIMD score (SES)† 1.07 (1.01; 1.12) 1.11 (1.05; 1.18) 1.09 (1.05; 1.13) 11
R-years of education 1.08 (1.02; 1.14) 1.09 (1.01; 1.18) 1.08 (1.03; 1.12) 12
Cigarettes/day† 1.06 (0.98; 1.13) 1.13 (1.02; 1.24) 1.07 (1.02; 1.14) 13
R-LDL-cholesterol 1.08 (1.01; 1.15) 1.05 (0.97; 1.14) 1.06 (1.01; 1.12) 14
Cystatin-C 1.07 (1.02; 1.13) 1.04 (0.98; 1.10) 1.06 (1.02; 1.09) 14
Homocysteine 1.08 (1.02; 1.13) 1.02 (0.94; 1.11) 1.06 (1.02; 1.10) 14
Insulin 1.04 (1.00; 1.09) 1.07 (1.02; 1.12) 1.05 (1.02; 1.09) 17
Peripheral Arterial Disease: Best Model
Men 291 Women 208 All 499 Rank
Binary
Diabetes mellitus† 3.56 (2.14; 5.92) 3.49 (1.80; 6.76) 3.38 (2.23; 5.13) 1
Tobacco smoker 1.74 (1.18; 2.58) 2.76 (1.68; 4.53) 2.15 (1.58; 2.93) 2
Sex: male/female† 1.59 (1.30; 1.96) 3
Family history of CHD† 1.51 (1.18; 1.94) 1.35 (1.02; 1.79) 1.44 (1.20; 1.74) 4
Continuous
Age† 1.55 (1.34; 1.80) 1.65 (1.38; 1.97) 1.62 (1.45; 1.81) 1
hsC-reactive protein 1.37 (1.19; 1.58) 1.51 (1.27; 1.80) 1.42 (1.27; 1.59) 2
Systolic blood pressure† 1.30 (1.15; 1.45) 1.28 (1.13; 1.45) 1.30 (1.19; 1.42) 3
Expired carbon monoxide 1.20 (1.05; 1.37) 1.32 (1.13; 1.54) 1.24 (1.13; 1.38) 4
Cotinine 1.26 (1.04; 1.53) 1.22 (0.96; 1.55) 1.24 (1.06; 1.45) 4
SIMD score (SES)† 1.26 (1.12; 1.42) 1.20 (1.04; 1.38) 1.24 (1.13; 1.36) 6
Lipoprotein (a) 1.12 (0.94; 1.34) 1.56 (0.96; 2.53) 1.21 (1.04; 1.42) 7
R-25OHD (adj) 1.32 (1.10; 1.59) 1.05 (0.81; 1.37) 1.20 (1.03; 1.41) 8
NT-pro-BNP 1.24 (1.08; 1.42) 1.16 (0.95; 1.42) 1.19 (1.06; 1.34) 9
Glucose 1.22 (1.12; 1.33) 1.12 (1.01; 1.23) 1.18 (1.11; 1.24) 10
Continued
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Table 5. Continued
Peripheral Arterial Disease: Best Model
Men 291 Women 208 All 499 Rank
Triglycerides 1.03 (0.91; 1.17) 1.34 (1.13; 1.58) 1.16 (1.04; 1.29) 11
Cystatin-C 1.10 (0.99; 1.22) 1.10 (0.97; 1.25) 1.10 (1.02; 1.19) 12
Coronary Heart Disease: Extended ASSIGN
Men 1847 Women 1251 All 3098 Rank
Binary
Diabetes mellitus† 2.19 (1.66; 2.89) 2.20 (1.59; 3.04) 2.24 (1.82; 2.76) 1
Sex: male/female† 2.04 (1.82; 2.27) 2
Family history of CHD† 1.36 (1.23; 1.50) 1.53 (1.36; 1.71) 1.43 (1.32; 1.54) 3
Continuous
Age† 1.34 (1.27; 1.42) 1.48 (1.37; 1.60) 1.38 (1.32; 1.45) 1
Total cholesterol† 1.39 (1.31; 1.49) 1.23 (1.14; 1.32) 1.33 (1.26; 1.39) 2
hsTroponin I 1.21 (1.04; 1.38)) 1.24 (1.12; 1.36) 1.22 (1.13; 1.33) 3
NT-pro-BNP 1.21 (1.14; 1.28) 1.20 (1.10; 1.30) 1.20 (1.14; 1.26) 4
Cotinine 1.17 (1.09; 1.26) 1.14 (1.04; 1.25) 1.16 (1.09; 1.23) 5
C-reactive protein 1.11 (1.03; 1.21) 1.23 (1.13; 1.34) 1.16 (1.09; 1.24) 5
Systolic blood pressure† 1.15 (1.09; 1.21) 1.11 (1.05; 1.17) 1.14 (1.09; 1.18) 7
R-Apolipoprotein-A 1.11 (1.04; 1.20) 1.16 (1.05; 1.28) 1.14 (1.08; 1.20) 7
SIMD score (SES)† 1.08 (1.03; 1.14) 1.12 (1.06; 1.19) 1.10 (1.06; 1.15) 9
R-Height 1.08 (1.01; 1.15) 1.14 (1.04; 1.25) 1.10 (1.04; 1.16) 9
R-years of education 1.09 (1.02; 1.15) 1.09 (1.01; 1.18) 1.09 (1.03; 1.14) 11
Cigarettes/day† 1.06 (0.99; 1.14) 1.13 (1.02; 1.25) 1.08 (1.02; 1.14) 12
Insulin (non-fasting) 1.06 (1.02; 1.10) 1.08 (1.03; 1.13) 1.07 (1.04; 1.10) 13
Cystatin-C 1.08 (1.03; 1.14) 1.04 (0.99; 1.10) 1.07 (1.03; 1.10) 14
R-LDL-cholesterol 1.08 (1.01; 1.14) 1.04 (0.97; 1.12) 1.06 (1.01; 1.12) 15
R-HDL cholesterol† 1.06 (1.00; 1.14) 1.03 (0.94; 1.12) 1.05 (1.00; 1.10) 16
Peripheral Arterial Disease: Extended ASSIGN
Men 291 Women 208 All 499 Rank
Binary
Diabetes mellitus† 3.58 (2.15; 5.96) 3.23 (1.68; 6.23) 3.36 (2.21; 5.10) 1
Sex: male/female† 1.79 (1.43; 2.22) 2
Family history of CHD† 1.50 (1.17; 1.92) 1.36 (1.03; 1.81) 1.44 (1.20; 1.73) 3
Continuous
Age† 1.56 (1.34; 1.82) 1.67 (1.38; 2.01) 1.62 (1.44; 1.81) 1
Thiocyanate 1.42 (1.13; 1.80) 1.36 (1.03; 1.80) 1.43 (1.20; 1.71) 2
hsC-reactive protein 1.37 (1.18; 1.59) 1.49 (1.25; 1.77) 1.41 (1.26; 1.59) 3
Systolic blood pressure† 1.34 (1.17; 1.55) 1.36 (1.18; 1.58) 1.36 (1.23; 1.51) 4
SIMD score (SES)† 1.31 (1.16; 1.47) 1.21 (1.05; 1.40) 1.28 (1.17; 1.41) 5
Lipoprotein (a) 1.12 (0.94; 1.34) 1.58 (0.94; 2.63) 1.21 (1.04; 1.41) 6
Expired carbon monoxide 1.14 (0.99; 1.32) 1.29 (1.10; 1.52) 1.20 (1.08; 1.33) 7
Cotinine 1.19 (0.95; 1.51) 1.25 (0.96; 1.63) 1.20 (1.00; 1.44) 7
NT-pro-BNP 1.24 (1.08; 1.42) 1.14 (0.92; 1.42) 1.19 (1.05; 1.35) 9
Continued
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Because the incidence of clinical PAD overall is one sixth that for
CHD, the risk of PAD in nonsmoking nondiabetic participants is
necessarily small. Of nonsmoking nondiabetics at recruitment,
15.9% in 20 years developed CHD versus only 1.1% PAD. Of
smoking diabetics, 43.3% developed CHD versus 17.3% PAD:
CHD risk increased 2.7-fold, versus PAD risk 16-fold. This
explains higher c-statistics and net reclassiﬁcation improve-
ments in PAD than CHD (see Table 6).
Methodological Issues: Why Factors Disappear,
Reverse Their HR Gradients, or Substitute for
Each Other
Adjustment, after age and sex, for other ASSIGN factors
reduces some HRs to insigniﬁcance, even reversal. Adjust-
ment in modeling also leads to some gradient reversals. This
applies to closely correlated factors—the stronger survive,
causing rivals to diminish or turn tail—but chance will operate
between those closely matched (see Table 7 for correlation
coefﬁcients of competing variables). For example:
1. In the best model for CHD, total cholesterol has a more
positive HR than in Table 3, whereas that for LDL-
cholesterol is now reversed.
2. In the above model, HDL-cholesterol, associated with a
number of factors, is relegated to insigniﬁcance; a major
detractor presumably is apolipoprotein-A.
3. Both total cholesterol and HDL-cholesterol are lost from
the PAD best model where other lipids have taken over.
4. Nonfasting glucose contributes to PAD, whereas nonfast-
ing insulin contributes to CHD.
5. Adjusted 25OHD survives into the best model for PAD; raw
values into extended ASSIGN.
6. Fibrinogen disappears from all models in the presence of
hsCRP.
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Table 5. Continued
Peripheral Arterial Disease: Extended ASSIGN
Men 291 Women 208 All 499 Rank
R-25OHD (raw) 1.27 (1.06; 1.52) 1.09 (0.80; 1.47) 1.19 (1.02; 1.41) 9
Glucose 1.23 (1.12; 1.34) 1.13 (1.02; 1.24) 1.18 (1.12; 1.25) 11
Triglycerides 1.04 (0.90; 1.19) 1.31 (1.09; 1.59) 1.15 (1.02; 1.29) 12
R-DBP 1.09 (0.94; 1.27) 1.12 (0.97; 1.32) 1.11(1.00; 1.23) 13
Cystatin-C 1.10 (0.99; 1.22) 1.10 (0.97; 1.25) 1.10 (1.02; 1.19) 14
Cigarettes/day† 1.04 (0.88; 1.21) 1.11 (0.89; 1.39) 1.06 (0.93; 1.20) 15
Total cholesterol† 1.06 (0.91; 1.23) 1.02 (0.85; 1.21) 1.05 (0.94; 1.17) 16
HDL cholesterol† 1.05 (0.94; 1.18) 0.94 (0.80; 1.11) 1.01 (0.91; 1.11) 17
This table replicates data for the best parsimonious models of CHD and PAD in the Figure for the sexes combined, but additionally gives sex-speciﬁc data for these models, and everything
is then repeated for the extended ASSIGN parsimonious models. Hazard ratios are per standard deviation change for continuous variables, some log transformed (see Table 1).
†ASSIGN risk score factors.
Table 6. C-Statistic and Net Reclassiﬁcation Improvement (with 95% Conﬁdence Limits) From Old to New Predictive Models
Coronary Heart Disease Peripheral Arterial Disease
Men Women Total Men Women Total
1847 1251 3098 291 208 499
C-statistic
ASSIGN variable model 0.690 0.734 0.723 (0.713; 0.734) 0.798 0.837 0.821 (0.795; 0.847)
Best model 0.712 0.750 0.741 (0.730; 0.751) 0.836 0.875 0.854 (0.828; 0.880)
Extended ASSIGN 0.712 0.750 0.740 (0.730; 0.751) 0.838 0.875 0.855 (0.829; 0.881)
Change in c-statistic from ASSIGN variable to improved models
Best model 0.022 0.016 0.018 (0.010; 0.025) 0.038 0.037 0.034 (0.023; 0.044)
Extended ASSIGN 0.021 0.016 0.017 (0.013; 0.021) 0.040 0.037 0.035 (0.024; 0.046)
Net reclassification improvement from ASSIGN variable to improved models
Best model 0.069 0.072 0.056 (0.032; 0.080) 0.115 0.363 0.231 (0.148; 0.313)
Extended ASSIGN 0.064 0.077 0.048 (0.025; 0.071) 0.127 0.372 0.186 (0.107; 0.265)
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7. Cigarette equivalent dose, an ASSIGN factor, appears in all
models except the best model for PAD, where it is ousted
by the yes/no tobacco smoker question, which in turn is
supplanted in extended ASSIGN for PAD by cigarette dose,
plus all 3 smoking biochemistry factors, with thiocyanate
now dominant.
These interactions explain why factors that appear signif-
icantly predictive in our Table 3 and in many publications do
not appear in the parsimonious models in the Figure and
Table 5—they have not been so challenged. Maybe factors we
have not measured will someday challenge those that we have.
Symptom Questionnaires and Baseline ECG as
Predictors
Data on sensitivity and speciﬁcity of the symptom question-
naires and ECG are shown in Table 2. A minority of clinical
events over 20 years were anticipated by these items. More
surprising is the low percentage of baseline questionnaire
positives who subsequently developed clinical disease (the
positive predictive value). Either the questionnaires are
nonspeciﬁc or preclinical atheromatous disease may improve
or fail to progress. Earlier cross-sectional studies gave the
Edinburgh claudication questionnaire high sensitivity and
speciﬁcity.12
Speciﬁc Predictors and the Overall Picture of
Contrasting Hierarchies
Linked to the question of which factors are in or out of the
contrasting models for CHD and PAD, is the ranking of those
factors within each model, even those present in both (see
Figure, Table 5). Although diabetes mellitus, sex, family
history of CHD, and age lead the hierarchy for both end
points, with cotinine nearing the top and cystatin-c nearing
the bottom, there is incongruity in other leaders. In PAD, total
cholesterol and hsTroponin I, found in CHD, are supplanted by
hsCRP and systolic blood pressure, suggesting that inﬂam-
mation outranks lipids and is a real advance predictor and not
secondary to severe arterial damage.26
Diabetes Mellitus and Insulin Resistance
Diabetesmellitus was the dominant factor in all models in terms
of HR. However, the percentage of diabetics in the baseline
population was unusually low (1.5%), contributing a small
percentage of PAD cases during follow-up–40/499 (8.0%). Even
with incident diabetes mellitus codiagnosed with PAD cases by
the end of follow-up, it was 137/499 (27.5%). Results for CHD
were 102/3098 (3.3%) and 512/3098 (16.5%). So diabetes
mellitus was important, but not the dominant cause of PAD, as
is sometimes believed. It may become so as its prevalence
Table 7. Pearson Correlation Coefﬁcients Between Associated/Competing Variables in the SHHEC Population, Sexes Combined
Lipids HDL-C Non-HDL Triglyceridess LDL-C Apo-A Apo-B Lipo (a)
Total cholesterol 0.191 0.940 0.320 0.566 0.167 0.792 0.183
HDL-cholesterol 0.156 0.409 0.067 0.787 0.208 0.039
Non-HDL-cholesterol 0.462 0.558 0.099 0.872 0.176
Triglycerides 0.004 0.194 0.438 0.014
LDL-cholesterol 0.044 0.445 0.045
Apolipoprotein A 0.055 0.045
Apolipoprotein B 0.160
Smoking variables ExpCO Thiocyanate Cotinine
Cigarettes per d 0.736 0.764 0.817
Expired carbon monoxide 0.747 0.765
Thiocyanate 0.795
Inflammatory Fibrinogen
hsC-reactive protein 0.413
Vitamin D Raw*
25OHD adjusted* 0.865
Renal related Creatinine
Cystatin-C 0.457
All results are highly statistically signiﬁcant. Apo-A indicates apolipoprotein A; Apo-B, apolipoprotein B; HDL, high-density lipoprotein; hs, high sensitivity; LDL, low- density lipoprotein;
SHHEC, Scottish Heart Health Extended Cohort; 25OHD, 25-hydroxyvitamin D.
*25-Hydroxyvitamin D before and after adjusting for seasonal variation using month of measurement.
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increases. We did not have fasting specimens or measure
HbA1c,
28,29 but our results for nonfasting insulin and glucose
suggest an additional role for insulin resistance.
Tobacco Smoking
All 5 smoking variables are interrelated and predictive of both
CHD and PAD (Tables 3, 4, and 7). Two smoking variables,
cigarette dose and cotinine, sufﬁce for the CHD models,
whereas the best PAD model includes 3, and extended
ASSIGN for PAD includes 4 (Table 5). Although interrelated,
they independently contributed to enhanced prediction in the
presence of others. Cotinine appeared the most powerful
smoking biomarker for CHD, and thiocyanate for PAD
(Table 3).
Tobacco smoking was a dominant risk factor for PAD.
Although 45.7% of all SHHEC participants were tobacco
smokers at recruitment, it was 55.0% for future CHD, and
77.8% for future PAD. Childhood smoking which is not
analyzed here, has been reported elsewhere as an indepen-
dent predictor for PAD.30
Physical Measurements
BMI was omitted from the ASSIGN cardiovascular score15 as
weak and inconsistent between the sexes. Physical measure-
ments were reexamined with this longer follow-up of SHHEC.
Examined alone (Tables 3 and 4) BMI is predictive in both
sexes for CHD but not for PAD. Other physical measurements
are also inconsistent between the end points. Waist circum-
ference survives into 1 CHD model but not both, whereas
height enters both. Systolic blood pressure is predictive in all
4 models and is the only physical factor in the PAD best
model; its stronger weighting in the extended ASSIGN model
for PAD is counterbalanced by a negative gradient for diastolic
blood pressure, as also seen in Table 3 after adjustment for
ASSIGN variables but not before. This suggests a role for
pulse pressure, which fell out of this model but is reported
elsewhere,31 and is evidence of aging and loss of elasticity in
the arterial tree.32 Others have found BMI predictive for PAD,
but with smokers and nonsmokers separated.33 In SHHEC
smokers of both sexes had BMI averaging 1.0 kg/m2 less
than in nonsmokers, possibly confounding our ﬁnding that
BMI was not predictive.
Lipids
Addition of variables to the earlier ASSIGN 9 changes
signiﬁcant lipids for both end points. In CHD, for both
models, total cholesterol remains signiﬁcant, with apolipopro-
tein A an interloper along with LDL-cholesterol (weak but
reversing its gradient from Table 3), but HDL-cholesterol is
squeezed into insigniﬁcance. In the PAD models, both total
cholesterol and HDL-cholesterol lack signiﬁcance although
both are predictive in isolation (Table 3); but lipoprotein (a)
becomes a contributory lipid34,35 along with nonfasting
triglycerides. Disappearance of HDL-cholesterol was dis-
cussed earlier. The dominance of total cholesterol in the
CHD models and its disappearance in PAD suggest differ-
ences in pathogenesis. A recent histological analysis of
occlusive PAD lesions in amputation specimens reports the
absence of lipids, but these were end-stage and presumably
followed medication.36 PAD is common in heterozygous
familial hypercholesterolemia, which is against serum choles-
terol having no role at all.37
Newer Biomarkers
hsTroponin I, NT-pro-BNP, and hsCRP (in that order) enter the
parsimonious models for CHD. For PAD, hsCRP outranks NT-
pro-BNP, but hsTroponin I fails to qualify. In both, cystatin-C
ﬁgures low down in the list, knocking out a weaker
creatinine. Using the same database as here, we recently
concluded that 25OHD, although predictive in isolation, failed
to be independently predictive for CVD after multiple
adjustment.38 Negative results for CHD and positive results
for PAD are intriguing in these analyses, with adjusted
25OHD weakly predictive in the best model but raw 25OHD
supplanting it in extended ASSIGN. Previously published
results are commonly cross-sectional, a problem for ascer-
taining causality.39,40
Clinical and Etiological Signiﬁcance of These
Results
The results of this study are of interest in causation but do not
necessarily mean that separate risk scores for different
cardiovascular end points would be useful. Clinically diag-
nosed PAD is delayed, less frequent (3.2% over 20 years in
those disease-free at measurement), and often follows the
onset of CHD, so its independent prediction is of lesser
clinical interest than CVD as a whole. Risk factors that we
measured are not all routinely available and would involve
costs and delays if made so. Omission of any 1 would alter the
models, necessitating recalculation. Some factors are positive
predictors in isolation but negative in combination with
others, creating possible confusion. Clinicians most con-
cerned with risk of PAD are diabetes mellitus physicians;
diabetics under care are the subject of other cohort studies.
For generalists assessing the apparently healthy, our results
suggest that although diabetes mellitus is a major risk factor,
it is not the most prevalent. Tobacco smoking is, with self-
report being reinforced by biochemical measures of intake
and of inﬂammation.
Prediction of CHD and PAD are improved by adding new
factors. Not surprisingly in CHD, for which 8 of the 9 ASSIGN
Twenty-Year Predictors of PAD Compared With CHD Tunstall-Pedoe et al
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factors remain in the new models, the c-statistic for the
ASSIGN 9 alone is high at 0.723 and modestly improved in the
2 parsimonious models, For PAD this is 7 out of 9; the c-
statistic is very high for the ASSIGN model (0.821), and there
is a large change in the 2 new models (0.854 and 0.855) with
associated NRI results.
These results place newer biomarkers into context (as well
as some now-neglected older ones) but demonstrate once
again the importance of diabetes mellitus and smoking in the
etiology of PAD, in contrast to CHD, where blame is more
evenly distributed. Family history of CHD and socioeconomic
status, adopted into the ASSIGN cardiovascular risk score in
2007,15 maintain their importance as predictors for both end
points, against potential interlopers.
The question of why atheromatous disease in vessel walls of
different arteries at different sites, exposed to the same blood
medium, should have disparate determinants, is unanswered,
but there must be differences in the reactivity of these arterial
walls.6,7,25 These results take the question a stage further: is
atherothrombosis 1 disease or a cluster of overlapping
diseases, with cholesterol in CHD largely supplanted by
inﬂammation,26,28,41 diabetes mellitus, and smoking in PAD?
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